Getting Under the Skin With GPP: Understanding and Treating a Rare Dermatologic Disorder - Live Webcast September 28, 2023 Pretest (ID: i879-2)

To assist us in evaluating the effectiveness of this activity, please complete the following pretest.
1.Which of the following best describes your profession?(Required.)
2.Which of the following best describes your specialty?(Required.)
3.How confident are you in the management of patients with GPP in your practice? (Required.)
4.GPP is characterized by which of the following? (Required.)
5.Which of the following is the most common comorbidity of GPP? (Required.)
6.Populations that are more frequently affected by GPP include which of the following? (Required.)
7.GPP is an autoimmune disorder caused mostly by mutations in which gene? (Required.)
8.IL-36 receptor antagonists improve or resolve symptoms and sequelae of GPP by binding to the IL-36 receptor, which prevents what? (Required.)
9.In the Effisayil 1 trial of 53 patients with GPP, what percentage of patients taking spesolimab achieved the primary endpoint of GPPGA score of 0 or 1 (clear or almost clear skin) by week 1 vs 6% of those taking placebo? (Required.)
10.Andrea, a 42-year-old woman with a history of GPP, lives in fear of when her next flare might occur. She has been relying on oral corticosteroids to prevent flare and is afraid to go off them because she knows that systemic steroid withdrawal is a common trigger for flare. Which treatment might be best to prevent GPP flare? (Required.)
11.An online survey of 66 people living with GPP in the United States found which of the following two activities were most severely affected by GPP flare? (Required.)
12.Contact Information(Required.)